Beyond Air

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Beyond Air and other ETFs, options, and stocks.

About XAIR

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. 

CEO
Steven A. Lisi
CEOSteven A. Lisi
Employees
61
Employees61
Headquarters
Garden City, New York
HeadquartersGarden City, New York
Founded
2015
Founded2015
Employees
61
Employees61

XAIR Key Statistics

Market cap
33.29M
Market cap33.29M
Price-Earnings ratio
-0.29
Price-Earnings ratio-0.29
Dividend yield
Dividend yield
Average volume
41.00M
Average volume41.00M
High today
$2.20
High today$2.20
Low today
$1.58
Low today$1.58
Open price
$1.74
Open price$1.74
Volume
15.11M
Volume15.11M
52 Week high
$10.40
52 Week high$10.40
52 Week low
$0.6733
52 Week low$0.6733

Stock Snapshot

Beyond Air(XAIR) stock is priced at $1.67, giving the company a market capitalization of 33.29M. It carries a P/E multiple of -0.29.

On 2026-01-14, Beyond Air(XAIR) stock moved within a range of $1.58 to $2.20. With shares now at $1.67, the stock is trading +5.7% above its intraday low and -24.1% below the session's peak.

Trading activity shows a volume of 15.11M, compared to an average daily volume of 41M.

The stock's 52-week range extends from a low of $0.67 to a high of $10.40.

The stock's 52-week range extends from a low of $0.67 to a high of $10.40.

XAIR News

TipRanks 1d
XTL Biopharmaceuticals Moves to Acquire NeuroNOS Stake from Beyond Air and Plans $2 Million Private Placement

Claim 70% Off TipRanks Premium XTL Biopharmaceuticals Sponsored ADR ( (XTLB) ) has shared an announcement. On January 13, 2026, XTL Biopharmaceuticals Ltd. si...

TipRanks 1d
XTL Biopharmaceuticals to acquire 85% of Beyond Air’s NeuroNOS for $32.5M

XTL Biopharmaceuticals (XTLB) announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air (XAIR), a biotechnology company pioneeri...

People also own

Based on the portfolios of people who own XAIR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .